Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.
Overview
Johnson & Johnson (NYSE:JNJ) is a holding company that generates revenue by researching, developing, and manufacturing products across its innovative medicine and medical technology segments.
The company recently entered a definitive agreement to acquire Firefly Bio, and it reported about a 22% net income margin for the quarter ended June 28, 2026.
Details
Eli Lilly (NYSE:LLY) is a global pharmaceutical company that earns its revenue by developing and commercializing human medicines, offering a comprehensive suite of diabetes and oncology medications.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.